BioLife Solutions, Inc. Stock

Equities

BLFS

US09062W2044

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
21.48 USD -1.24% Intraday chart for BioLife Solutions, Inc. -1.10% +32.18%
Sales 2024 * 109M Sales 2025 * 122M Capitalization 989M
Net income 2024 * -25M Net income 2025 * -15M EV / Sales 2024 * 9.06 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 8.14 x
P/E ratio 2024 *
-38.4 x
P/E ratio 2025 *
-66.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.55%
More Fundamentals * Assessed data
Dynamic Chart
BioLife Solutions Introduces the CellSeal CryoCase? at International Society for Cell & Gene Therapies Conference in Vancouver CI
Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target MT
Earnings Flash (BLFS) BIOLIFE SOLUTIONS Posts Q1 Revenue $31.7M, vs. Street Est of $24.9M MT
Transcript : BioLife Solutions, Inc., Q1 2024 Earnings Call, May 09, 2024
BioLife Solutions, Inc. Affirms Revenue Guidance for the Year 2024 CI
BioLife Solutions, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
BioLife Solutions Completes Divestment of Global Cooling Subsidiary MT
An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. for $2.6 million. CI
Jefferies Initiates Coverage on BioLife Solutions With Buy Rating, $22 Price Target MT
BioLife Solutions, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : BioLife Solutions, Inc., Q4 2023 Earnings Call, Feb 29, 2024
BioLife Solutions, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Biolife Solutions Announces Preliminary Unaudited Revenue Results for Fourth Quarter and Full Year 2023 CI
Lake Street Adjusts BioLife Solutions Price Target to $15 From $25, Maintains Buy Rating MT
Transcript : BioLife Solutions, Inc., Q3 2023 Earnings Call, Nov 09, 2023
More news
1 day-1.24%
1 week-1.10%
1 month+22.88%
3 months+19.53%
6 months+62.11%
Current year+32.18%
More quotes
1 week
21.17
Extreme 21.17
22.35
1 month
17.15
Extreme 17.15
23.10
Current year
14.50
Extreme 14.5
23.10
1 year
8.92
Extreme 8.9201
24.50
3 years
8.92
Extreme 8.9201
60.67
5 years
7.37
Extreme 7.37
60.67
10 years
1.43
Extreme 1.4328
60.67
More quotes
Managers TitleAgeSince
Founder 52 97-12-31
Chief Executive Officer 63 16-03-03
Director of Finance/CFO 39 14-12-31
Members of the board TitleAgeSince
Chief Executive Officer 63 16-03-03
Director/Board Member 62 13-11-17
Director/Board Member 62 22-08-31
More insiders
Date Price Change Volume
24-05-31 21.48 -1.24% 253,789
24-05-30 21.75 +0.74% 218,772
24-05-29 21.59 -2.44% 296,696
24-05-28 22.13 +1.89% 475,565
24-05-24 21.72 +2.99% 237,623

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Its expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. Its biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death which result when cells and tissues are subjected to reduced temperatures. Its bioproduction tools portfolio includes human platelet lysates for cell expansion. It is a provider of biological and pharmaceutical storage and cold chain logistics. Its monitoring systems allow customers real time tracking of the storage temperatures of their materials throughout the logistics process. It operates about five storage facilities in the United States and one facility in the Netherlands.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
21.48 USD
Average target price
24.78 USD
Spread / Average Target
+15.35%
Consensus